id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-A-0099-0005,FDA,FDA-2007-A-0099,"Response Letter from FDA CDER to GlaxoSmithKline, Wilmer Cutler Pickering Hale and Dorr LLP,  Ropes & Gray LLP,  Novo Nordisk Inc. and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP",Other,Response(s),2020-06-01T04:00:00Z,2020,6,2020-06-01T04:00:00Z,,2020-06-02T02:12:05Z,,0,0,09000064846c252f